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Crystal structure of a 30 kDa C-terminal fragment from the
g chain of human fibrinogen
Vivien C Yee1,2, Kathleen P Pratt1, Hélène CF Côté1, Isolde Le Trong2,3,
Dominic W Chung1, Earl W Davie1, Ronald E Stenkamp2,3 and 
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Background: Blood coagulation occurs by a cascade of zymogen activation
resulting from minor proteolysis. The final stage of coagulation involves thrombin
generation and limited proteolysis of fibrinogen to give spontaneously
polymerizing fibrin. The resulting fibrin network is covalently crosslinked by factor
XIIIa to yield a stable blood clot. Fibrinogen is a 340 kDa glycoprotein composed
of six polypeptide chains, (abg)2, held together by 29 disulfide bonds. The
globular C terminus of the g chain contains a fibrin-polymerization surface, the
principal factor XIIIa crosslinking site, the platelet receptor recognition site, and a
calcium-binding site. Structural information on this domain should thus prove
helpful in understanding clot formation.
Results: The X-ray crystallographic structure of the 30 kDa globular C terminus
of the g chain of human fibrinogen has been determined in one crystal form using
multiple isomorphous replacement methods. The refined coordinates were used
to solve the structure in two more crystal forms by molecular replacement; the
crystal structures have been refined against diffraction data to either 2.5 Å or
2.1 Å resolution. Three domains were identified in the structure, including a
C-terminal fibrin-polymerization domain (P), which contains a single
calcium-binding site and a deep binding pocket that provides the polymerization
surface. The overall structure has a pronounced dipole moment, and the
C-terminal residues appear highly flexible.
Conclusions: The polymerization domain in the g chain is the most variable
among a family of fibrinogen-related proteins and contains many acidic residues.
These residues contribute to the molecular dipole moment in the structure, which
may allow electrostatic steering to guide the alignment of fibrin monomers during
the polymerization process. The flexibility of the C-terminal residues, which
contain one of the factor XIIIa crosslinking sites and the platelet receptor
recognition site, may be important in the function of this domain.
Introduction
Fibrinogen is a large glycoprotein (molecular weight
340KDa) circulating in blood. It is composed of six
polypeptide chains (abg)2 arranged as two linked units,
each containing an a, b and g chain (Fig. 1). The protein
appears as a trinodular structure in electron micrographs
with a central nodule that contains the N-terminal regions
of all six polypeptide chains [1,2]. The two distal nodules
contain the C-terminal regions of the polypeptide chains
and are joined to the central nodule by two separate triple-
stranded coiled-coil regions [3,4]. The overall length of the
molecule is 450Å.
In the final stages of the coagulation cascade, fibrinogen is
converted to fibrin by thrombin. In this reaction, fib-
rinopeptides are released from the N-termini of the two
a chains, leading to rapid polymerization of the fibrin
monomers. Fibrinopeptides are also released from the
N-termini of the two b chains, but at a much slower rate.
Protofibrils are generated initially as the fibrin monomers
align in half-staggered and overlapping strands, showing a
thickness of two molecules [5,6]. This alignment involves
the newly generated N terminus of the a chain of one
molecule binding to the C-terminal region of a g chain of
an adjacent molecule [7]. As the fibrin strands grow longer
and thicker, the molecules are linked covalently by factor
XIIIa, primarily through crosslinking of the g chains [8,9].
The C-terminal region of the g chain also participates in
platelet plug formation, in which fibrinogen binds to and
forms a bridge between activated platelets [10], during the
aggregation phase of platelet plug formation. Fibrinogen
contains three bound calcium ions [11], two of which are
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located in the C-terminal region of the g chain; the third
calcium ion is present in the central nodule [12]. Calcium
accelerates fibrin formation [13], and also stabilizes the
protein against proteolysis [14] and heat denaturation [15].
The goal of the present study was to establish the three-
dimensional structure of the C-terminal region of the
g chain of fibrinogen by X-ray crystallography. A recombi-
nant 30kDa fragment from the C-terminal region of the
human g chain, which had been expressed in yeast, was
isolated and crystallized for the structure determination.
This fragment contains part of the polymerization surface
of fibrin, a calcium-binding site, and the factor XIII cross-
linking site. The results presented here demonstrate that
this portion of the fibrin molecule possesses a unique fold,
and the structural properties of the fragment provide
several exciting insights into the mechanism of fibrin poly-
merization, the crosslinking of fibrin by factor XIIIa,
platelet aggregation reactions, and calcium binding.
Results and discussion
The three-dimensional structure of a recombinant 30kDa
C-terminal fragment of the human fibrinogen g chain
(rFbggC30), containing residues Val143 to Val411 has been
determined in three different crystal forms. The P21 crystal
form was first solved by multiple isomorphous replacement
methods. The resulting model, consisting of residues
Gln144 to Leu392, one calcium ion, and 177 solvent mol-
ecules, has been refined against 10.0–2.1Å resolution dif-
fraction data to give a crystallographic R value of 15.9%.
Two additional crystal forms with space groups R3 and
P21212 were solved by molecular replacement using the
protein coordinates of the refined P21 structure. The R3
structure contains two independent molecules, the first
model spans residues Gln144 to Gly403, and in the second
residues Val143 to Leu392 and Gly397 to Gly403 are
observed. The final R3 model, which includes one calcium
ion per protein molecule and 202 solvent atoms, was
refined against 10.0–2.5Å resolution data to yield an
R value of 17.1%. In the P21212 crystal form, residues
Gln144 to Leu402, one calcium ion, and 151 solvent mol-
ecules were observed and refined against 10.0–2.1Å resolu-
tion diffraction data to give a final R value of 17.0%.
Overall molecular structure 
The rFbggC30 fragment has a unique overall fold; no
similar structure could be identified by using the com-
puter program DEJAVU [16] or in a search of the
Structural Classification of Proteins (SCOP) database [17].
The fragment is prolate ellipsoidal with dimensions of
approximately 38×44×56Å. There are three well defined
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Schematic representation of the fibrinogen molecule. The a, b, and g
chains are indicated, as well as their N and C termini. The purple
hexagons represent N-linked glycosylations, while the small black
triangles indicate the sites of thrombin cleavage. The region of the
molecule encompassing the rFbggC30 fragment is depicted in black.
(Adapted from RF Doolittle.)
domains which pack sequentially in the globular body of
the rFbggC30 structure (Fig. 2). At the N terminus, the
small A domain (Val143–Trp191) contains a twisted three-
stranded antiparallel b sheet flanked by a short helix. As
shown in Figure 2 this b structure consists of two sequen-
tial hairpin turns; the region of overlap, which forms the
sheet, occurs only at residues Cys182 and Glu183. A disul-
fide bond (Cys153–Cys182) anchors the helix to the
middle strand of the sheet. The second and central B
domain (Thr192–Ala286 and Lys380–Leu392) contains a
seven-stranded antiparallel b sheet with two short helices
and a hairpin loop aligned against one of its faces. The two
b strands of this sheet adjacent to the B-1 loop of
Figure 2a (residues Phe215–His217 and Glu225–Trp227)
are distorted relative to the other five strands of the sheet.
A notable feature of the b sheet is that its middle strand is
formed by the insertion of residues near the C terminus of
the molecule (Lys381–Pro388). Little regular secondary
structure is found in the third, or P, domain (Gly287–
Met379), which is composed predominantly of loops. One
of the two lobes in the P domain contains two short
helices and the second disulfide bond (Cys326–Cys339) in
the molecule. The preponderance of loops and the
remarkably limited secondary structure in domain P are
consistent with the high glycine content (13 of 94 amino
acids) and suggest that this domain may be more flexible
than domains A and B; atomic temperature factors indi-
cate, however, that the A domain is the most mobile of the
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Figure 2
Structure of rFbggC30 in the P21 crystal
form. (a) The stereo ribbon diagram is colored
by domains: A in cyan, B in purple, and P in
green. The calcium ion is shown as a gray
sphere; sidechains in the two disulfide bonds
are drawn as ball-and-stick structures. Also
labeled are the N and C termini of the chain,
the polymerization pocket (PP) in the P
domain, the sidechain of Tyr363 in the
polymerization pocket, and the five variable
loops (B-1, P-1 to P-4) described in the text.
(b) Stereo diagram of the Ca trace with every
10th residue marked by a black sphere and
every 20th residue labeled. The calcium ion is
shown as a large gray sphere and labeled for
reference. MOLSCRIPT [56] was used to
generate (a) and (b) and Raster3D [57] was
used to generate (a) only.
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three. In the P21 crystal form, the average temperature
factor for the A, B, and P domains are 16.3, 9.6, and
12.1Å2, respectively. This pattern of average temperature
factors for the three domains is similar in the R3 and
P21212 structures. The two reported plasmin cleavage
sites (Lys302 and Lys356) [18] in the fragment are located
in the P domain and have sidechains that are exposed to
solvent and thus accessible to proteolytic cleavage.
Calcium-binding site
Fibrin polymerization and crosslinking are calcium-depen-
dent processes. A single calcium-binding site in the
rFbggC30 molecule has been identified in all three crystal
forms, and coincides with the heavy atom position of the
TbCl3 derivative. The amino acid residues that bind the
calcium ion are in a small loop (P-2) in the P domain
(Fig. 3a,b), one end of which is connected to the rest of the
domain by the Cys326–Cys339 disulfide bond. This disul-
fide bond has an important structural role, as revealed by
the fact that Cys339 and Asn337 (which forms a mainchain
hydrogen bond with Cys339) are the only two non-glycine
residues in the structure that have glycine- like mainchain
angles in the Ramachandran plot. Seven oxygen atoms
coordinate the calcium ion in a geometry that is approxi-
mately octahedral. The oxygen atoms are provided by the
sidechain carboxylate moieties of Asp318 and Asp320,
along with the mainchain carbonyl groups of Phe322 and
Gly324 and two solvent molecules (W501, W502) (Fig.
3b). Calcium to oxygen distances were not restrained
during refinement. In the P21 structure, six of these dis-
tances are between 2.37 and 2.53Å ,whereas the seventh
(between the calcium and one of the two Asp318 carboxy-
late oxygen atoms) is longer, at 2.82Å. This binding site is
also the location of a defect in a congenitally abnormal fib-
rinogen, in which residues Asn319 and Asp320 are missing;
this abnormal protein exhibits impaired calcium binding
and fibrin polymerization [19]. Asp318, Asp320, and
Gly324 are conserved among all the fibrinogen g chain
sequences. The conservation of Gly324 reflects the impor-
tance of the conformation of this loop for cation binding.
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Figure 3
The calcium-binding site in the P21 crystal
form of rFbggC30. (a) Stereo view of the
2Fo–Fc electron-density map calculated using
phases from the final refined coordinates,
contoured at 1s level. The protein model is
shown as thick bonds; the calcium ion, its
protein ligands (residues 318, 320, 322, and
324) and two coordinating solvent molecules
are labeled. (b) Stereo view of the calcium-
binding loop P-2 with the protein mainchain,
coordinating acidic sidechain groups, calcium
ion, and bound solvent molecules drawn as
ball-and-stick structures. Part (a) was
produced by O [43] and part (b) was drawn
using MOLSCRIPT [56]. 
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Equilibrium-dialysis binding studies have shown that the
calcium-binding site encompasses the region of residues
303–355/356 [20]. Terbium fluorescence studies localized
the calcium-binding site to residues 311–336 [21], consis-
tent with our assignment of the protein ligands. A calcium-
binding site has been predicted to be in this acidic region,
but the predictions were for an EF-hand motif [21] or for 
a site similar to the cation site in the mannose-binding
protein [18]. A comparison of the fibrinogen calcium-
binding site with known EF-hand structures [22] and 
with rat mannose-binding protein [23] shows no notable
similarity in the cation-binding sites, however. The short
Asp318–Gly324 calcium-binding loop in rFbggC30 differs
significantly from all of the calcium binding structures cur-
rently accessible in the Protein Data Bank [22]. Thus, the
rFbggC30 structure adds one more to the wide variety of
already known calcium-binding structural motifs [24].
Polymerization pocket
The conversion of fibrinogen to give spontaneously poly-
merizing fibrin is initiated when thrombin cleaves the fib-
rinopeptide A from each a chain to expose new N termini.
These new termini then bind to the C-terminal moieties
in the g chains of adjacent, aligned fibrin molecules. Solu-
tion studies with small labeled peptide inhibitors (such as
GPRK) that mimic the N terminus of the fibrin a chain
have localized the polymerization surface to residues
337–379 of the fibrinogen g chain [25], specifically the
region around residue Tyr363 [26]. In the rFbggC30 struc-
ture, Tyr363 is a partially exposed residue (Fig. 2a) that,
together with the calcium-binding loop, lines a deep
pocket called the polymerization pocket or PP. The loca-
tion of this binding pocket has been confirmed in studies
of the structure of the rFbggC30 co-crystallized with the
Gly–Pro–Arg–Pro amide (KPP et al., unpublished results),
showing that it occupies a space between the loops of
domain P (Fig. 2a). It is significant that a portion of the PP
surface is formed by residues that are conserved among
the fibrinogen g chain sequences, but diverge when the
complete family of aligned sequences is considered
(Fig. 4). Furthermore, 13 residues (between residues 143
and 411 of the fibrinogen g chain) have been identified as
sites of amino acid substitutions, deletions or insertions
that lead to calcium-binding defects and/or impaired poly-
merization. Three of these mutation sites (Gln329 [27],
Asp330 [28], and Arg375 [29]) involve sidechains that are
partially exposed and line the surface of the PP pocket.
Variable surface loops
A structure-guided alignment of 30 sequences of the C-
terminal portions of fibrinogen g and b chains and related
proteins was performed to investigate the degree of struc-
tural similarity to be expected in this family of protein
regions. This alignment was used to generate the dendro-
gram in Figure 4a. Representative sequences for each major
group of Figure 4a are aligned in Figure 4b. The protein
sequences share from 34% to 99% sequence identity with
the human fibrinogen g chain and are thus expected to
have the same protein fold. Most of the 24 residues that are
absolutely identical among the 30 sequences have side-
chains that are buried in rFbggC30, or are disulfide cys-
teines or glycines, and are clearly structurally important. In
contrast, the 133 residues that are conserved among the
g-chain sequences are distributed throughout the interior
and on the surface of the structure, and are expected to be
important both structurally and functionally.
To test the hypothesis that the C-terminal regions of the b
and g chains share a similar fold, the experimental g chain
coordinates were combined with sequence alignment
information to construct a homology model of the C termi-
nus of the human b chain (which is 42% identical to
rFbggC30). Both the experimental rFbggC30 structure
and the modeled b-chain structure were analyzed using a
residue environment profile method and were found to
have scores higher than the average for properly folded
proteins of their size [30]. There are three sites of notable
structural difference between the C-terminal fragments of
the human fibrinogen g and b chains. The first is an
eight-residue insertion in the B-1 loop of the b chain,
between two b strands in the B domain (Figs 2a, 4b). The
inserted sequence in the fibrinogen b chain contains a cys-
teine residue which forms a disulfide bond with the N ter-
minus of the A domain. In the rFbggC30 structure, loop
B-1 is solvent-exposed and close to the N terminus. The
loop insertion and additional disulfide bond in the b chain
are not expected to cause significant changes in conforma-
tion in other parts of the structure.
The second pronounced difference between the g-chain
structure and the b-chain model is found in the P-1 loop. In
the g chain of fibrinogen this region contains five conserved
aspartic acid residues and presents a negatively-charged
surface, whereas the corresponding loop in the fibrinogen
b chain is the same length but lacks this acidic character.
The third difference is the insertion of five residues in the
P-2 loop of the b chain of fibrinogen, which is the loop
that contains the calcium binding site in the g chain. This
insertion would be expected to alter the conformation of
the P-2 loop dramatically, since one end is tethered to 
the rest of the domain by a disulfide bond. The altered
conformation would explain the lack of calcium binding in
the fibrinogen b chain despite the fact that the calcium
ligands, Asp318 and Asp320, are conserved. Differences in
the sequence of loop P-1 and the insertion in loop P-2
alter the structural and electrostatic properties of the P
domain in the b-chain model. In addition, most of the
residues lining the PP pocket in rFbggC30 are different in
the b-chain sequence. Taken together, the differences in
structure and sequence in the P domain are consistent
with the g chain being more important in the initial stages
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of fibrin polymerization than the b chain. These changes
would also account for the absence of a calcium-binding
site in the b chain, despite a protein fold that is probably
conserved in the b chain.
The structure-guided sequence alignment shown in
Figure 4b also directs attention to two loops in the P
domain that are very different from the corresponding
regions in the non-fibrinogen sequences. Loops P-1 and P-3
have similar lengths in the g and b chains of fibrinogen but
are dramatically truncated by three to fourteen residues in
the non-fibrinogen sequences. The shortening of the P-1
and P-3 loops is expected to result in the absence of the P-
domain pocket in these proteins. Another significant alter-
ation occurs in the T lymphocyte proteins (in Group IV),
which have deletions of nine residues in the P-1 loop and
insertion of eight residues into the P-4 loop. This P-4 loop
precedes the C-terminal b strand of the B domain and is
coupled with a truncation of the P-3 loop. One possible con-
sequence of this eight-residue insertion would be to com-
pensate, in part, for the P-1 and P-3 deletions by providing
a new, extended surface for the P domain. In rFbggC30,
the P domain contains many of the structural determinants
of the protein’s function. Sequence alignments show that
this domain varies the most among the proteins expected to
share the same fold. The pronounced structural variability
in this functionally important domain reflects the diversity
of function in this family, members of which bind to pro-
teins or to saccharides, or whose ligands, if any, are yet to be
identified.
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Molecular dipole
The loops in the P domain are important structural features,
since they provide the calcium-binding site and form the
polymerization pocket. The calculated surface electrostatic
potential of the rFbggC30 structure shows that these loops
also provide the largest areas of negatively charged surface
(Fig. 5). The concentration of acidic residues in the P
domain results in a large molecular dipole moment (477.7
Debye for the P21 structure) along the long axis of the frag-
ment. A similar calculation with the homology model of 
the fibrinogen b chain fragment gives a much smaller mol-
ecular dipole moment (137.1 Debye) at an angle of ~70° to
the long axis of the structure. Thus the dipole moment of
the g chain is expected to dominate at the distal nodules 
of the fibrinogen molecule. Electron microscopy has shown
that fibrin polymerization begins with the formation of
double-stranded protofibrils, in which adjacent strands are
aligned in a half-staggered, end-to-middle domain pairing.
It is likely that the long-range, regular arrangement of fibrils
is due not only to the specific, but limited interaction
between the g chain polymerization pocket and the N ter-
minus of the a chain, but also to the substantial dipole
moment of the rFbggC30 fragment.
Crosslinking sites
There is some controversy as to whether factor XIIIa cat-
alyzes the formation of longitudinal crosslinks between
fibrin g chains aligned end to end in the same fibril [31] or
transverse crosslinks between g chains in adjacent fibrils
[32] (Fig. 6). Based on the location of various known posi-
tions in the fibrin molecule, the 225Å fibrin repeat distance
observed in electron-microscopy studies, and the dimen-
sions of the rFbggC30 structure, it is possible to calculate
the distance for a transverse crosslink (Fig. 6) with the fol-
lowing assumptions: first, the disulfide bond marking the
twofold-symmetry axis in fibrin is formed between Cys28
on each of the two a chains in fibrin. Second, the N-termi-
nal Gly17, and several additional residues of the a chain of
one fibrin monomer fit into the polymerization pocket of an
adjacent fibrin monomer, while an additional nine residues
from the a chain lie outside the pocket. Third, the linear
distance from the binding pocket to residue 392 in the
g chain is approximately 35Å. Residue 392 is the last one
with a fixed position in all three crystal structures. Fourth,
ten more residues will extend from residue 392 to the mid-
point of the reciprocal factor XIII crosslinks. Accordingly,
the distance for 19 residues along with the 35Å mentioned
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Figure 4 continued
Dendrogram and representative sequences from the structure-
guided sequence alignment of fibrinogen-related proteins. (a)
Dendrogram of the aligned sequences. Each protein was given a
number; the first three alphabetic characters of each name define the
type of protein fragment and the last two describe the species. The
protein sequences are divided into six groups as follows: group I,
fibrin g chains, proteins 1–6; group II, fibrin b chains, proteins 7–11;
group III, extended a chains, proteins 12–13; group IV, fibrin related
sequences, proteins 14–16; group V, ficolins and invertebrate
proteins, proteins 17–21; group VI, tenascins and homologs,
proteins 22–30. In this dendrogram, the branch lengths are natural
logarithms of the steps between nodes (see Materials and methods).
(b) Sequence alignment of a representative human protein from each
of the major groups in Figure 4a. The order of the six proteins is the
same as the group label of Figure 4a. The first row of numbers are
the sequence positions of rFbggC30 in fibrinogen. Residues or gap
positions identical within the group represented by the sequence are
printed in red. Those residues identical in all 30 proteins are printed
in green. Secondary structure is indicated by arrows (b strands) or
rectangles (a helices). Secondary structure assignment has only
been made up to residue 392. The loops labeled B-1 and P-1 to P-4
are discussed in the text. The broken box surrounding residues
318–324 delineates the calcium-binding loop. Gaps occurring in all
proteins indicate one or more of the proteins is longer than the
representative sequences at the gapped location. 
The proteins included in the sequence alignment and the
dendrogram together with the reference, SWISS-PROT or PIR
identifier are as follows: 1 FbG Hu, P02679, human (Homo sapiens)
fibrinogen g A chain, residues 143–411; 2 FbH Hu, P04469, human
fibrinogen g B (g′) chain, residues 143–427; 3 FbG Bo, P12799,
bovine (Bos taurus) fibrinogen g B chain (g′), residues 143–420;
4 FbG Rt, P02680, rat (Rattus norvegicus) fibrinogen g A and B
chain, residues 144–420; 5 FbG Xe, P17634, African clawed frog
(Xenopus laevis) fibrinogen g chain, residues 141–413; 6 FbG SL,
P04115, sea lamprey (Petromyzon marinus) fibrinogen g chain,
residues 144–408; 7 FbB Hu, P02675, human fibrinogen b chain,
residues 201–461; 8 FbB Rt, P14480, rat fibrinogen b chain
(fragments), residues 58–310; 9 FbB Bo, P02676, bovine fibrinogen
b chain, residues 187–447; 10 FbB Ck, Q02020, chicken (Gallus
gallus) fibrinogen b chain (fragment), residues 205–463; 11 FbB SL,
P02678, sea lamprey fibrinogen b chain (fragment), residues
220–477; 12 FbE Hu, B44234, human a chain, extended form (a E)
residues 18–262; 13 Fb2 SL, P33573, sea lamprey fibrinogen a-2
chain, residues 371–617; 14 FbR Hu, JN0596, human fibrinogen-
related protein HFREP-1, residues 73–312; 15 T49 Hu, S47273,
human pT49 fibrinogen-like T-lymphocyte protein, residues
203–439; 16 FbX Ms, P12804, mouse (Mus musculus) cytotoxic
T-lymphocyte specific protein, residues 177–413; 17 SCA Dr,
P21520, Drosophila melanogaster scabrous protein, residues
488–689; 18 Fic Hu, human ficolin, [58], residues 99–313;
19 FiA Po, A47172, porcine (Sus scrofa) ficolin a, residues
109–323; 20 FiB Po, B47172, porcine ficolin b, residues 112–326;
21 FbA SC, P19477, sea cucumber (Parastichopus parvimensis)
fibrinogen-like protein A (FREP-A), residues 36–258; 22 FbL Hu,
P22105, human XB gene overlapping P450c21B, residues
596–820; 23 TnH Po, S28170, porcine tenascin homolog
(fragment), residues 1–220; 24 TnR Hu, human tenascin-R, janusin,
J1-160/180, [59] residues 1128–1358; 25 TnN Rt, S32023, rat
neural recognition molecule J1-160/180, residues 1126–1356;
26 TnN Ck, JH0675, chicken restrictin, neural extracellular matrix,
residues 1123–1353; 27 TnA Hu, P24821, human tenascin,
residues 1953-2177; 28 TnA Po, S19694, porcine tenascin
precursor, residues 1521–1746; 29 TnA Ms, JQ1322, mouse
tenascin precursor, residues 1794–2019; 30 TnA Ck, P10039,
chicken tenascin precursor, residues 1583–1808. Further
information on this figure is available as Supplementary material
(published with this paper on the Internet).
above is needed to reach halfway between a chain globular
domains (Fig. 6). Thus the equation for the distance
becomes 19x+35=225/2, where x is the linear distance that
must be covered by each residue and 225Å is the half-
length of the fibrin monomer. The value of x is approxi-
mately 4Å, a number too large to span the Ca–Ca length of
a peptide (3.8Å). As predicted in Figure 6, the distance
indicated by the label ‘T’ is longer by 7.6Å than available
in peptides plus the distance through the rFbggC30 frag-
ment. With the more appropriate figure of 3.5Å as the
mean residue length in an extended peptide, the discrep-
ancy increases to 19Å. Although the calculation is rough,
the requirements for maximal extension of the polypeptide
chain and colinearity of the three segments of the line allow
us to conclude that transverse crosslinking of the a chains
in linear fibrin fibrils is unlikely.
Flexible C terminus
Fibrin polymerization yields a soft blood clot which is ren-
dered mechanically stable and far more resistant to pro-
teolysis after covalent crosslinking by factor XIIIa. The C
terminus of the g chain contains the Gln398/Gln399 amine
acceptor and Lys406 donor residues that are crosslinked [9],
as well as the platelet receptor binding site [10]. In the
rFbggC30 P21 structure, amino acids beyond Leu392 are
not visible in any of the electron density maps. HPLC
analysis of a cyanogen bromide digest of rFbggC30 (similar
to that from which the P21 crystals were grown) showed the
presence of three species that differed at the C terminus.
Mass spectroscopic analysis revealed: one major component
ending at His400 and minor components ending at Ala408
and Gly409, a full length protein ending at Val411, and a
fragment ending at His401 (data not shown). Since mass
spectroscopy of the P21 crystals themselves failed, it is not
known whether the missing residues Thr393–Val411 are
invisible due to proteolysis or because they are disordered. 
To address this issue, we purified a new batch of protein
that was stabilized throughout the purification by the pres-
ence of protease inhibitors (N-ethyl maleimide (NEM),
phenylmethylsulfonyl fluoride (PMSF), aprotinin and
pepstatin A). The crystals grew in group P21212 under
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Figure 6
Schematic representation of the longitudinal
(L) versus transverse (T) end-to-end g–g
crosslinking between adjacent fibrin
molecules.
L
T
35 Å
150 Å
225 Å
Figure 5
Molecular dipole moment of the rFbggC30
structure. (a) Accessible surface with positive
and negative electrostatic potential colored
blue and red, respectively. The head of the
yellow arrow, representing the pronounced
molecular dipole moment, is seen at the top of
the figure. (b) Coil drawing of the structure in
the same orientation as (a), with the dipole
moment drawn as a large yellow arrow. The
three domains are colored separately and the
calcium ion is shown as a gray sphere. The N
and C termini of the chain, as well as the
polymerization pocket (PP), are also labeled.
Figure was produced using GRASP [60].
crystallization conditions identical to those that produced
P21 crystals in the absence of inhibitors (see Materials and
methods). In the R3 and P21212 crystal structures, the last
visible residues are Gly403 and Leu402, respectively. Mass
spectroscopic analysis of the protein solution with protease
inhibitors present (NEM and PMSF) and of the data collec-
tion crystals indicated the presence of components ending
at Gly403 and at Ala405 (data not shown).
The C-terminal regions (beyond residue Leu392) in the two
crystallographically-independent molecules of the R3
crystal form and the C-terminal region in the P21212 struc-
ture are found in three different conformations. These
differences appear to be due to the different local crystal
packing environments. All of the residues observed beyond
Leu392 in the three conformations form intermolecular con-
tacts and/or hydrogen bonds. Residues Thr393– Glu396 are
visible in electron-density maps only for molecule 1 in the
R3 space group; the corresponding region in molecule 2 is is
not visible in the maps. The two independent R3 molecules
and that in the P21212 space group have similar intermolec-
ular mainchain hydrogen bonding. This may be significant
because in each case the hydrogen bonding corresponds to
that in b strands. It is tempting to speculate that the ten-
dency of the Gln399–His402 segment to form b strands may
be important in the alignment of the C termini during the
factor XIIIa covalent crosslinking process.
Despite some similarity in the intermolecular hydrogen-
bonding patterns involving the C-terminal regions in the R3
and P21212 crystal forms, the three peptides are found in
dramatically different positions and orientations relative 
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Figure 7 Figure 7 continued
Superpositions of extended C-terminal residues. (a) Coil drawing of
the three superimposed rFbggC30 structures. The globular portion of
the protein, consisting of residues 144–392, is colored and labeled by
domain (A in cyan, B in purple, and P in green); the calcium ion is
shown as a gray sphere and labeled, along with the N terminus of the
chain. The C-terminal regions of molecules 1 and 2 in the R3 crystal
(R1 light green and R2 pale blue), and of the P21212 structure (01,
lavender) are labeled in red and drawn as peptide coils with
superimposed sidechain groups in ball-and-stick form. Residues 393
to 396 of molecule 2 in the R3 crystal could not be traced in the
electron-density maps; this missing segment is shown as a string of
small pale blue spheres. (b) The C-terminal regions of the rFbggC30
structures are superimposed, along with residues 398 to 411 from a
lysozyme fusion protein X-ray structure (PDB identifier 1LSG). Ca
atoms for residues 398–401 were used to generate the superposition.
The three rFbggC30 structures are colored as in (a) and labeled at
their N-termini; the peptide from the lysozyme fusion protein is colored
dark green and is labeled at its C terminus. (c) Detailed view of the
four superimposed C-terminal regions shown in (b), with all common
sidechain groups labeled. The paths of the termini are shown as
strings of spheres which are in the same color as the corresponding
region. As in (b), the N termini of the three rFbggC30 structures are
labeled in blue and the C terminus of the lysozyme fusion structure is
labeled in red. Figure was drawn using MOLSCRIPT [56].
to the globular three-domain body of the protein (Fig. 7a).
Different crystal packing interactions account for these
large differences. When only the extended C-terminal
regions are superimposed (Figs 7b, c), another view of the
conformational differences among the peptides is provided.
Also included in the comparison is the structure of the
Gln398–Val411 region, as determined in a crystallographic
study of the peptide fused to the C terminus of chicken
egg-white lysozyme (PDB identifier 1LSG) [33]. The posi-
tions of the four common Ca atoms (from Gln398 to
His401) used in the superposition agree well, but the main-
chain of the peptides on either side of this short segment
deviate substantially. On a local level, the sidechain confor-
mations also differ significantly from each other (Fig. 7c).
One factor XIIIa crosslinking site, Gln398, is present in all
four structures, and its sidechain is found in four different
conformations. The other crosslinking site, Lys406, is only
observed in the lysozyme fusion protein; however, its posi-
tion and orientation relative to the Gln398 residue are not
compatible with the peptide conformations observed in the
R3 and P21212 crystal structures, because their C-terminal
residues (Leu402 or Gly403) are in very different positions.
The ability of the g-chain C-terminal residues to adopt dif-
ferent conformations due to differing intermolecular inter-
actions is consistent with other structural results. Solution
NMR studies at pH3 of a Lys385–Val411 peptide indicated
that residues Asn390–Leu402 adopt a multiple-turn, or
helix-like structure, whereas residues 403–411 were struc-
turally nondescript [34]. Other solution NMR studies have
been conducted on the Leu392– Val411 peptide, which
binds to monoclonal antibody 4A5 [35]. These experiments,
carried out at pH5.2, revealed that the structural features
necessary for binding of the peptide to the platelet receptor
were considerably different from those necessary for anti-
body binding [35]. This implies that the conformation of
the peptide must  be different in these two interactions.
Finally, an NMR study of the peptide His400–Val411 inter-
acting with the integrin GPIIb/IIIa platelet receptor used
distance geometry calculations based on transfer NOE
measurements to demonstrate that the peptide was helical
when bound to the platelet receptor [36].
The multiple conformations observed for the C-terminal
region Thr393–Val411 provide firm evidence that this
region is flexible. The C-terminal region is highly suscepti-
ble to proteolysis (HCFC, unpublished data) and indeed,
mass spectrometry of some of the solutions from which the
crystals were grown and two of the crystals themselves
indicated that these samples contained protein that was
proteolyzed to some degree at the C terminus. Because of
this, we cannot fully rule out the possibility that the full-
length protein may provide additional stabilizing interac-
tions that ‘anchor’ this region in a single conformation.
Efforts are continuing to produce and crystallize intact
rFbggC30. Our working hypothesis at present is that the
flexibility in the C-terminal region is physiologically
important, allowing the protein to adapt to crosslinking by
factor XIIIa and platelet-receptor binding by adopting dif-
ferent conformations.
Implications of the rFbggC30 structure
Historically, understanding of the process of fibrin polymer-
ization and factor XIIIa-catalyzed crosslinking has been
limited by a lack of detailed structural information. Recent
crystallographic studies of factor XIIIa have shown that the
active site of the enzyme is buried in both the zymogen
(inactive) and in the thrombin-cleaved forms [37,38]. It is
clear, however, that a conformational change in the enzyme
must occur to make the active site accessible to its sub-
strate. The fibrin substrate is itself a cofactor in factor XIII
activation, as indicated by solution studies [39]. The confor-
mational flexibility in the crosslinking site of the g chain of
fibrinogen, as indicated in this X-ray crystallographic study
and other published NMR solution studies, suggests that
conformational changes occur (both in the substrate and in
the factor XIIIa enzyme) during the crosslinking process.
The pronounced molecular dipole described in this work
suggests an orientation mechanism for fibrin alignment
during the polymerization process. Finally, the elucidation
of the structural details of the calcium-binding site and the
polymerization pocket provide valuable information for the
design of high affinity fibrin ligands targeted at the g chain
of fibrinogen.
Biological implications
Vascular damage leads to platelet plug formation and the
generation of an insoluble fibrin clot at the site of injury.
Fibrinogen is critical in these reactions, which are respon-
sible for reducing, then arresting the loss of blood. Initially,
fibrinogen forms a bridge between activated platelets as
the platelet plug is being generated. This is followed by
fibrin generation, polymerization and crosslinking to yield
a more stable platelet plug.
The C-terminal portion of the g chain of fibrinogen has 
a significant role in these reactions. It contains the region
that binds to activated platelets, the polymerization pocket,
the crosslinking site and a calcium-binding site. The three-
dimensional structure of a C-terminal fragment of the g
chain of human fibrinogen (rFbggC30) has made it pos-
sible to identify and locate the polymerization pocket, as
well as the single calcium-binding site in the molecule.
Specific amino acid residues that line the polymerization
pocket include Tyr363, which was identified earlier as
part of the polymerization site [26]. Seven oxygen atoms
coordinate the calcium ion. These atoms are provided by
specific aspartic acid residues and mainchain atoms of
phenylalanine and glycine, which form the short Asp318–
Gly324 calcium-binding loop, in addition to two water
molecules. These data clearly establish the requirement
for calcium in fibrin formation and fibrinogen stability.
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In addition to these well established molecular features,
this structure suggests several intriguing possibilities.
First, the structure-guided sequence alignment of the C
termini of a variety of extracellular proteins places this
fragment of the fibrin molecule into a biological context
not normally considered for fibrin. The sequence and phy-
logenetic analysis shows this globular portion of the fibrin
molecule is a member of a family of proteins that bind
diverse ligands such as proteins and saccharides. Second,
the finding of an impressive molecular dipole moment for
rFbggC30, substantially larger than that calculated for the
b-chain model, suggests the possibility of electrostatic
steering as a significant component of the fibrin polymer-
ization mechanism. Third, the question of whether factor
XIIIa crosslinking reactions of fibrin are transverse or
longitudinal can now be addressed, and we find the trans-
verse crosslink unlikely. Finally, two of the crystal forms
examined possess three different conformations for the
C-terminal residues beyond residue 392. This information,
taken together with a diversity of conformations observed
by others both in solution and in crystals, suggests that
conformational flexibility of the C terminus of the g chains
is functionally important in its biological context.
Materials and methods
Preparation of rFbggC30
A fragment from the C terminus of the g chain of human fibrinogen
encoding residues Val143–Val411 was expressed in the methylotrophic
yeast Pichia pastoris (strain GS115) according to the manufacturer’s
protocol (Invitrogen, San Diego, CA). The vector, pPIC9K, was kindly
provided by Dr Michael Romanos (Wellcome Research Laboratories).
The recombinant protein (rFbggC30) was purified to homogeneity by
ammonium sulfate precipitation, followed by cation-exchange chro-
matography. rFbggC30 inhibited the polymerization of desAfibrin in
batroxobin-initiated fibrinogen clotting assays (data not shown), indicat-
ing that the polymerization site is biologically functional within this frag-
ment. Moreover, the fragment was readily crosslinked by recombinant
human factor XIIIa, a gift from Dr Paul Bishop (ZymoGenetics Inc.,
Seattle, WA) (data not shown).
Crystallization
Monoclinic crystals of rFbggC30 (space group P21, unit cell parame-
ters a = 37.53 Å, b = 68.42 Å, c = 47.67 Å and b= 105.36°) were grown
at room temperature by sitting drop vapor diffusion employing two dif-
ferent conditions: 20 % PEG3350 and 70 mM CaCl2 in 0.1 M Tris
buffered at pH 8.0; and 18 % PEG8000 and 70 mM CaCl2 in 0.1 M
MES buffered at pH 6.0. When a solution of rFbggC30 was stabilized
in a Tris/NaCl buffer containing the inhibitors NEM and PMSF at pH 7.4
and then dialyzed against a 5 mM MES solution containing NEM and
PMSF and buffered at pH 6.0, rhombohedral crystals (space group R3
unit cell parameters a = 164.65 Å and c = 84.88 Å) were grown. The
protein solution remaining from the dialysis experiment was used to
grow the orthorhombic crystal form (space group P21212, unit cell
parameters a = 48.70 Å, b = 61.58 Å, and c = 83.25 Å) by room temper-
ature sitting drop vapor diffusion under the same PEG8000 conditions
which yielded the original P21 crystals.
Data collection and preparation of heavy atom derivatives
Since the P21 crystals were obtained first, they were used in the initial
multiple isomorphous replacement (MIR)structure solution. K2PtCl4 and
UO2(NO3)2 derivatives were obtained by soaking pH6.0 crystals in artifi-
cial mother liquor with 5mM of the heavy atom compound added for 
one day. A TbCl3 derivative was obtained by first soaking in artificial
mother liquor containing no added calcium for two days, and then
soaking in the presence of 5mM TbCl3 at pH8.0 for two days. All diffrac-
tion data were collected on either of two systems, one a Siemens X1000
area detector equipped with a graphite monochromator, and the other 
a Rigaku Raxis-II imaging plate detector with focusing mirrors; each
apparatus was mounted on a Rigaku RU200 rotating anode X-ray
source supplying CuKa radiation. Siemens data were processed using
XENGEN [40] while Raxis data were processed using either Raxis soft-
ware or DENZO [41] (Table 1).
Phase determination and model building
The P21 derivative data sets were scaled to native data with KBRANI 
(S Mande and W Hol, unpublished data). Heavy atom sites for each
derivative were located by analysis of isomorphous difference Patterson
maps, and confirmed by difference Fourier syntheses. Programs in the
CCP4 suite [42] were used for heavy atom phase calculation and refine-
ment (MLPHARE) (Table 1), density modification (DM), and map calcula-
tion. Model building was carried out with O [43]. An initial polyalanine
model was built into 10.0–2.5Å resolution MIR and density-modified
MIR maps which resulted from implementation of the solvent flattening,
histogram matching, application of Sayre’s equation, and skeletonization
protocols in the CCP4 program DM. Phases calculated from the polyala-
nine model were combined with MIR phases using SIGMAA [42,44] to
yield improved electron-density maps into which a complete molecular
model could be built.
Crystallographic refinement
All refinement calculations were performed using energy minimization
and simulated annealing features in X-PLOR [45]. The starting R factor
for the P21 MIR model of 41.3 % (Rfree = 43.0 %) against data from
10.0 to 2.5 Å resolution dropped to 31.8 % (Rfree = 37.9 %) in one
round of energy minimization. Further refinement of the P21 model was
carried out by alternating between cycles of manual refitting in O with
X-PLOR energy minimization and simulated annealing calculations. In
the final stages of refinement, the resolution of the diffraction data
included in the calculations was extended to 10.0–2.1 Å (Table 2).
Molecular replacement
The R3 and P21212 structures were solved by molecular replacement
calculations with the refined P21 coordinates and the program AMoRe
[42]. Using 8.0–3.0Å resolution data, the two independent molecules
in the R3 crystal form, and the single molecule in the P21212 structure,
could be easily located. For the R3 structure, the molecular replace-
ment solution gave a correlation coefficient between calculated and
observed Patterson vectors and R factor of 77.5% and 28.9 % respec-
tively, while the corresponding values for the P21212 structure were
77.6 % and 30.1 %. Initial refinement of these two crystal forms was
carried out using 10.0–2.5Å resolution data. In the case of the P21212
crystal form, final refinement calculations included data from 10.0–2.1Å
resolution. For all three crystal forms, a random 10% of the diffraction
data were set aside for the Rfree calculation in order to monitor the
course of refinement (Table 2).
Calcium ions and solvent molecules were located in peaks in difference
Fourier maps before being included in the refinement. In the three crys-
tals, the same single calcium-binding site was found in each molecule
and its location corresponded to the highest peak of residual electron
density, which was greater than 10s in each case (s represents the
root mean square electron density for the unit cell). During the final
cycles of X-PLOR refinement, all diffraction data from 10.0 Å to the
high resolution limit were included.
Structure verification
Three different profile methods, 3D1D [30], PROSAII [46], and ERRAT
[47], all confirmed the compatibility of the rFbggC30 crystal structure
with its amino acid sequence. The program PROCHECK [48] was
used to assess the geometric quality of the three crystal structures and
determined that all were of above average stereochemical quality when
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compared with the reference database of structures deposited in the
Protein Data Bank.
Sequence alignment and homology modeling
The UWGCG package of programs [49] was used for extraction of pro-
teins from the SWISS-PROT and PIR databases. Family alignments
were performed by an updated [50] version of the algorithm described
earlier [51]. The PROFILESEARCH method [52] was used to search
both databases for further entries, which were then aligned with the
family; some newer sequences were entered manually. After the align-
ment of the sequences, the P21 model was examined for compatibility
with the alignment and the gaps and insertions moved, if necessary, to
positions compatible with the protein structure. In general this involved
moving a residue or two. The primary criterion for gap placement was
surface accessibility and loops; gaps within secondary structure ele-
ments were avoided whenever possible. Additionally, insertion and dele-
tion positions (gaps) were chosen to minimize any structural changes,
particularly in the core of the protein. The homology model of the b-
chain fragment was constructed from the sequence alignment using the
BIOSYM software [53].
The phylogenetic analysis of the aligned sequences was performed
using maximum parsimony with the PHYLIP package of programs [54].
The best trees were found using PROTPARS. The only uncertainty in
the trees concerned the relations among proteins 27, 28, and 29 of
Figure 4a. CONSENSE was used to determine the consensus tree
among the three possibilities. Following CONSENSE, the ANCSTR
program [55] was used to determine leg lengths in the tree. For plotting,
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Table 2
Refinement statistics.
Crystal P21 (native) R3 (native) P21212 (native)
Resolution (Å) 10.0–2.1 10.0–2.5 10.0–2.1
No. of reflections 11 854 26 046 15 050
Completeness (%) 87.8 89.1 98.9
No. of protein atoms 1995 4132 2070
No. of calcium ions 1 2 1
No. of solvent 177 202 151
Rcryst (%)* 15.5 16.8 16.7
Rfree (%)* 22.7 24.4 22.6
Rref (%)* 15.9 17.1 17.0
Rms deviations
bonds (Å) 0.009 0.010 0.009
angles (°) 1.656 1.737 1.699
dihedral angles (°) 24.495 24.274 23.948
improper torsion angles (°) 1.244 1.306 1.291
Protein mean B/max B (Å2) 11.8/65.0 21.5/88.5 15.1/72.5
Calcium B (Å2) 14.9 24.9, 32.4 11.1
Solvent mean B/max B (Å2) 31.4/60.7 38.6/77.7 28.6/60.1
Luzzati rms coordinate error (Å) 0.18 0.24 0.19
*Rcryst/Rfree/Rref = Σ || FPobs | – | FPcalc || / Σ | FPobs |, where Rfree was calculated using a random 10 % of the reflections, Rcryst was calculated using the
remaining 90 % of the reflections, and Rref was calculated after the final cycles of refinement in which all the data were used.
Table 1
Data collection and multiple isomorphous replacement phasing.
Crystal P21 (native) K2PtCl4 TbCl3 UO2 R3 (native) P21212 (native)
a (Å) 37.53 37.12 37.24 37.29 164.65 48.70
b (Å) 68.42 67.70 67.99 68.02 61.58
c (Å) 47.67 46.90 47.18 47.14 84.88 83.25
b (°) 105.36 105.01 105.36 105.31
VM (Å3/Da) 1.97 3.69 2.18
Detector Siemens Siemens Raxis Siemens Raxis Raxis
Resolution (Å) 33.0–2.0 33.9–2.0 37.8–2.1 31.8–2.0 33.3–2.5 50.0–2.0
Rsym(I) (%)* 3.33 3.19 5.87 5.12 8.3 6.1
Completeness (%) 82.7 85.3 89.8 76.4 89.2 94.6
Number of sites 1 1 4
Resolution (Å) 10.0–2.5 10.0–2.5 10.0–2.5
Riso (F) (%)† 14.6 9.6 14.2
Rcullis (centric/acentric)‡ 0.66/0.79 0.76/0.86 0.59/0.51
Phasing power (c/a)§ 1.05/1.32 0.75/0.95 1.77/2.91
*Rsym = Σ | Ih – < Ih > | / Σ Ih, †Riso = Σ || FPH | – | FP || / Σ | FPH |, ‡Rcullis = Σ | (FP + FHcalc) | – | FPH | / Σ || FPH | – | FH || and §Phasing power =
Σ | FHcalc | / Σ | (FP + FHcalc) – FPH |. Overall figures of merit for centric, acentric and all data are 0.87, 0.61 and 0.63, respectively.
the programs FITCH, RETREE, and DRAWTREE [54] were used. The
natural logarithms of the branch lengths were used for plotting Figure
4a. This operation allows the display of all of the sequences without
serious overlap of the labels in the figure. Thus the branch lengths in
Figure 4a indicate logarithmic distances among the proteins. 
Accession numbers
Coordinates for the three crystal forms have been deposited with the
Protein Data Bank (P21, R3, and P21212 structures with identifiers
1FIB, 1FIC, and 1FID, respectively).
Supplementary material
The supplementary material contains the 30 sequences which were
aligned to construct Figures 4a and 4b. The legend of Figure 4 gives
the names of each of the proteins, which are numbered and aligned in
the same order as in the Figure. This information is also available at
http://www.bmsc.washington.edu/people/teller.
Note added in proof
An abstract has recently appeared describing crystallography of frag-
ment D and derivatives (Doolittle, R.F., Spraggon, G., Everse, S.J., Veer-
apandian, L. & Riley, M. (1996). Crystal structure studies on fragment D
and double-D from human fibrinogen. Blood 88 (suppl. 1), 283).
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